Rhythm forced to wait for Imcivree expansion as FDA delays decision
The US Food and Drug Administration (FDA) has extended the review period for expanded approval of Rhythm Pharmaceuticals’ Imcivree (setmelanotide)…
All articles by Robert Barrie
Robert Barrie
Robert Barrie is a news and features reporter for Pharmaceutical Technology and Medical Device Network. Robert holds a BSc in Neuroscience and holds interests in neurological devices, infectious diseases, and company investment such as initial public offerings (IPOs). Contact Rob
-
-
Trump hits long-term pledge as US prices of weight loss drugs slashed
President Donald Trump achieved one of his key targets in the healthcare sector, following agreements with Eli Lilly and Novo…
-
J&J’s Caplyta wins MDD approval to extend revenue horizon
Caplyta (lumateperone) has scored a label extension into the depression setting, underscoring the belief Johnson & Johnson (J&J) saw in…
-
Former blockbuster Linzess grows label with paediatric IBS-C approval
The US Food and Drug Administration (FDA) has approved Linzess (linaclotide) as the first treatment for children living with irritable bowel…
-
Novo Nordisk latest outlook trim shows “quick momentum loss”
Novo Nordisk has cut its outlook for 2025 as lower expectations for glucagon-like peptide-1 receptor agonists (GLP-1RA) continue to hit…
-
MSD secures $700m for broad-cancer ADC asset
Antibody-drug conjugates (ADCs) continue to be à la mode in the oncology sector, with Merck & Co (MSD) tying up…
-
Tidmarsh’s FDA exit marks latest high-profile jockeying at US agencies
George Tidmarsh has resigned from the US Food and Drug Administration (FDA), becoming the latest in a long line of…
-
Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn
Kimberly-Clark has agreed to acquire Johnson & Johnson (J&J) consumer health spinout Kenvue for $48.7bn. One of America’s largest consumer…
-
Massive sales for weight loss drugs spur Eli Lilly’s Q3
As weight loss market rival Novo Nordisk drew headlines for starting a bidding war over a potential $9bn acquisition of…
-
Novo Nordisk locks horns with Pfizer in late bid for Metsera
Pfizer’s agreed takeover Metsera could be in jeopardy, after Novo Nordisk submitted a rival bid to acquire the obesity biotech.…